A novel dopamine receptor D2 antagonist (ONC206) potentiates the effects of olaparib in endometrial cancer.
Paraghamian SE, Qiu J, Hawkins GM, Zhao Z, Sun W, Fan Y, Zhang X, Suo H, Hao T, Prabhu VV, Allen JE, Zhou C, Bae-Jump V.
Paraghamian SE, et al.
Cancer Biol Ther. 2023 Dec 31;24(1):2202104. doi: 10.1080/15384047.2023.2202104.
Cancer Biol Ther. 2023.
PMID: 37069726
Free PMC article.